Explore the latest evidence in obesity management in this journal club review of the SURMOUNT-5 clinical trial, presented by Bharati Bhardwaja, PharmD, from Kaiser Permanente Colorado. This video breaks down a Phase 3b randomized trial comparing tirzepatide and semaglutide in adults with obesity without type 2 diabetes, highlighting key efficacy and safety outcomes over 72 weeks.

Learn how tirzepatide demonstrated superior weight loss compared to semaglutide, achieving an average 20.2% reduction in body weight versus 13.7%, along with significantly greater reductions in waist circumference. The discussion also reviews clinically meaningful weight loss thresholds, showing that more patients on tirzepatide achieved ≥10%, ≥15%, ≥20%, and even ≥30% weight reduction. Safety findings are also covered, including common gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting, as well as considerations during dose escalation.

Designed for healthcare professionals and clinicians managing obesity and metabolic disease, this video provides a clear, evidence-based comparison of two leading therapies, offering practical insights to guide treatment decisions and optimize patient outcomes in obesity care. For more expert-led education, visit the Content Rheum and stay up to date with the latest clinical insights in rheumatologic care.